lessthanhalf
Explorer
There's another news piece out of Australia covering adverse reactions to peptides. It's helpful since it includes at least a few concrete figures.
Since July 2025, Victoria has recorded 13 anaphylaxis cases attributed to peptides. That isn't especially shocking; it may actually be somewhat more frequent than you'd expect when comparing the volume of reports on this forum against how many people post, since I've come across roughly 3 that are or likely are anaphylaxis here.
The figure that stands out more is 1280 emergency department presentations in New South Wales over the past year, in a state with 8.6 million residents. There's no way to determine what share of those people use peptides, but it's still a fairly notable count. A good portion of those presentations would probably have occurred with the legitimate version of the GLP drug regardless—things like nausea and vomiting, gallstones, or accidental overdoses from dosing errors. I haven't come across many surveys estimating what percentage of the population uses peptides; it could range from one in a thousand up to a few percent. I'll try to track down where these numbers come from in case there's a breakdown of causes.
For people obtaining GLP drugs from a vetted group of vendors, I believe the benefits outweigh any added risks from black market peptides, largely because obesity carries such serious long-term risks that those are almost certainly going to be far worse than any peptide risks. For milder issues or peptides that are less well studied, though, the risk/benefit calculation gets more complicated.
Loading…
www.theage.com.au
Since July 2025, Victoria has recorded 13 anaphylaxis cases attributed to peptides. That isn't especially shocking; it may actually be somewhat more frequent than you'd expect when comparing the volume of reports on this forum against how many people post, since I've come across roughly 3 that are or likely are anaphylaxis here.
The figure that stands out more is 1280 emergency department presentations in New South Wales over the past year, in a state with 8.6 million residents. There's no way to determine what share of those people use peptides, but it's still a fairly notable count. A good portion of those presentations would probably have occurred with the legitimate version of the GLP drug regardless—things like nausea and vomiting, gallstones, or accidental overdoses from dosing errors. I haven't come across many surveys estimating what percentage of the population uses peptides; it could range from one in a thousand up to a few percent. I'll try to track down where these numbers come from in case there's a breakdown of causes.
For people obtaining GLP drugs from a vetted group of vendors, I believe the benefits outweigh any added risks from black market peptides, largely because obesity carries such serious long-term risks that those are almost certainly going to be far worse than any peptide risks. For milder issues or peptides that are less well studied, though, the risk/benefit calculation gets more complicated.
